A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2002
11/21/2002	US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002	US20020173655 Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal
11/21/2002	US20020173641 Nucleotide sequences coding polypeptides for use in human therapeutics, pharmacology and diagnostics
11/21/2002	US20020173550 Tetrahydrocannabinol; side effect reduction
11/21/2002	US20020173549 Compositions and methods for treatment of mild cognitive impairment
11/21/2002	US20020173543 Compounds for altering mitochondrial function and cellular responses
11/21/2002	US20020173540 Using plant extract
11/21/2002	US20020173531 Central nervous system disorders; psychological disorders
11/21/2002	US20020173528 Agonists specific for the peripheral cannabinoid receptor
11/21/2002	US20020173527 Tumor necrosis factor antagonist; antiinflammatory agents
11/21/2002	US20020173521 Inhibitors of copper-containing amine oxidases
11/21/2002	US20020173514 Pyridine-substituted pyrazolopyridine derivatives
11/21/2002	US20020173512 Psychological disorders; antidepressants
11/21/2002	US20020173511 Serotonergic compositions and methods for treatment of mild cognitive impairment
11/21/2002	US20020173510 Nutrient mixture; fatty acid, calcium compound and vitamins
11/21/2002	US20020173507 Antiproliferative agents; apoptosis; anticancer agents
11/21/2002	US20020173505 Antiserotonine agents; respiratory system disorders; antidepressants; eating disorders
11/21/2002	US20020173504 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
11/21/2002	US20020173503 Substituted pyridoindoles as serotonin agonists and antagonists
11/21/2002	US20020173500 Hypotensive agents; antiischemic agents
11/21/2002	US20020173499 Estrogen replacement therapy
11/21/2002	US20020173464 Modulation of pericyte proliferation
11/21/2002	US20020173458 Polypeptides; genetic engineering
11/21/2002	US20020173449 O-superfamily conotoxin peptides
11/21/2002	US20020172999 Novel KIAA1061-like cell adhesion molecule-like proteins and polynucleotides encoding them
11/21/2002	US20020172958 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
11/21/2002	US20020172727 Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
11/21/2002	US20020172661 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta (IFN-beata)
11/21/2002	DE10123952A1 New naphtho-1,2-thiazine compounds, useful as neuroprotectants for treating e.g. epilepsy or Alzheimer's disease, are allosteric modulators of AMPA receptors
11/21/2002	DE10112828C1 Preparation of high purity citalopram comprises a cyanide exchange reaction followed by thin film distillation and recrystallization from methanol and water
11/21/2002	CA2778114A1 Abuse-resistant opioid dosage form
11/21/2002	CA2740056A1 Methods and compositions for treating mammalian nerve tissue injuries
11/21/2002	CA2451116A1 Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
11/21/2002	CA2447593A1 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
11/21/2002	CA2447588A1 Dihydroimidazo [5,1-a]-$g(b)-carboline derivatives, method for preparing same and use thereof as medicine
11/21/2002	CA2447576A1 Use of hmg fragment as anti-inflammatory agents
11/21/2002	CA2447305A1 Novel 5-phenyl-1h-indole derivatives as antagonists of interleukine-8 receptors
11/21/2002	CA2447292A1 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	CA2447275A1 Therapeutic delivery of carbon monoxide
11/21/2002	CA2447184A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors
11/21/2002	CA2447150A1 Processes for the synthesis of derivatives of 2,3-dihydro-1,4-dioxino-[2,3-f] quinoline
11/21/2002	CA2447116A1 Methods for treating liver disease and liver damage with growth hormone and foxm1b
11/21/2002	CA2446988A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	CA2446980A1 Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
11/21/2002	CA2446957A1 Compaction process for manufacture of sodium phenytoin dosage form
11/21/2002	CA2446945A1 Method of preventing cell death using segments of neural thread proteins
11/21/2002	CA2446879A1 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors
11/21/2002	CA2446797A1 Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors
11/21/2002	CA2446751A1 Kavalactone compositions and methods of use
11/21/2002	CA2446740A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	CA2446717A1 Novel 4-anilinoquinoline-3-carboxamides
11/21/2002	CA2446641A1 Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
11/21/2002	CA2446586A1 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	CA2446127A1 Destruction of prions using vibriolysin or variants thereof
11/21/2002	CA2445922A1 Estrogen receptor modulators
11/21/2002	CA2445366A1 Molecules for disease detection and treatment
11/21/2002	CA2445003A1 Diarylurea derivatives useful as anti-inflammatory agents
11/21/2002	CA2443964A1 Use of osteopontin for the treatment and/or prevention of neurologic diseases
11/21/2002	CA2443721A1 Sulfonamide derivatives
11/21/2002	CA2443160A1 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof
11/20/2002	WO2001091755A1 Active substance combination containing a compound with an opioid effect and at least one further compound of formula i
11/20/2002	EP1258484A1 Novel isoxazole and thiazole compounds and use thereof as drugs
11/20/2002	EP1258474A2 Alkylamide compounds
11/20/2002	EP1258250A1 Nerve protective drugs
11/20/2002	EP1258246A2 Controlled release oxycodone compositions
11/20/2002	EP1258244A1 High affinity ligands for nociceptin receptor ORL-1
11/20/2002	EP1257646A2 Transporters and ion channels
11/20/2002	EP1257642A1 Partners of ptb1 domain of fe65, preparation and uses
11/20/2002	EP1257635A2 Lipid metabolism enzymes and polynucleotides encoding them
11/20/2002	EP1257633A1 Presenilin deficient multipotent cell lines and screening methods for intramembrane regulated proteolytic activities using these lines
11/20/2002	EP1257585A2 Antibodies that bind human interleukin-18 and methods of making and using
11/20/2002	EP1257584A2 Humanized antibodies that sequester amyloid beta peptide
11/20/2002	EP1257582A2 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity
11/20/2002	EP1257581A1 Compounds related to or derived from gfr alpha 4 and their use
11/20/2002	EP1257578A2 Transporters and ion channels
11/20/2002	EP1257555A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
11/20/2002	EP1257548A1 Benzofuran carboxamides and their therapeutic use
11/20/2002	EP1257547A1 1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists
11/20/2002	EP1257546A1 Kinase inhibitors
11/20/2002	EP1257545A1 SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS
11/20/2002	EP1257544A2 Piperazine and piperidine derivatives for treatment or prevention of neuronal damage
11/20/2002	EP1257543A1 Pyridinylimidazoles
11/20/2002	EP1257541A2 Polypharmacophoric agents
11/20/2002	EP1257539A2 Amino pyrazole derivatives useful for the treatment of obesity and other disorders
11/20/2002	EP1257535A1 Substituted pyridine compounds useful for controlling chemical synaptic transmission
11/20/2002	EP1257528A1 Aminoalcohol derivatives
11/20/2002	EP1257527A1 (2s)-aminoindan derivatives, a process for their preparation and their use as selective dopamine d3 ligands
11/20/2002	EP1257526A1 Aniline-derived ligands for the thyroid receptor
11/20/2002	EP1257298A1 Cosmid dna constructs and methods of making and using the same
11/20/2002	EP1257292A1 Use of il-18 inhibitors
11/20/2002	EP1257289A1 Immunotherapy using interleukin 13 receptor subunit alpha 2
11/20/2002	EP1257281A1 Nucleoside analogs with carboxamidine modified monocyclic base
11/20/2002	EP1257280A1 Drospirenone for hormone replacement therapy
11/20/2002	EP1257278A1 The use of mirtazapine for the treatment of sleep disorders
11/20/2002	EP1257277A2 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
11/20/2002	EP1257275A2 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
11/20/2002	EP1257272A1 Thiazolium compounds and treatments of disorders associated with protein aging
11/20/2002	EP1257271A1 Use of pramipexole for the treatment of addictive disorders
11/20/2002	EP1257264A1 Estrogen receptor modulators
11/20/2002	EP1257262A2 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof

1 ... 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 ... 1833